PTGS2 and neoplasm: Our findings highlighted several features of claudin-low breast cancer with potential therapeutic implications, including a low tumor mutational burden, high expression of the immune checkpoint gene CD274 (encoding PD-L1), and high expression of PTGS2 (encoding cyclooxygenase-2).